FDA approves Novartis' Afinitor as renal angiomyolipoma treatment

04/26/2012 | Medscape (free registration) · Fox Business

The FDA approved Novartis' Afinitor, or everolimus, to treat renal angiomyolipomas in patients with tuberous sclerosis complex. The drug previously was approved for patients with advanced renal cell cancer who failed to respond to treatment with Onyx Pharmaceuticals and Bayer HealthCare Pharmaceuticals' Nexavar or Pfizer's Sutent.

View Full Article in:

Medscape (free registration) · Fox Business

Published in Briefs: